natgillin/translations-raw huggingface dataset:
Caution should be exercised in patients with low leukocyte and/or neutrophil counts for any reason, in patients receiving medicines known to cause neutropenia, in patients with a history of drug-induced bone marrow depression/toxicity, in patients with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease. 
Oprez je potreban u bolesnika s niskim brojem leukocita i/ili neutrofila iz bilo kojeg razloga, u bolesnika koji primaju lijekove za koje se zna da uzrokuju neutropeniju, u bolesnika s depresijom/toksičnošću koštane srži uzrokovane lijekovima u anamnezi, u bolesnika s depresijom koštane srži uzrokovanom popratnom bolešću, zračenjem ili kemoterapijom te u bolesnika s hipereozinofilnim stanjima ili mijeloproliferativnom bolešću.
Olanzapine Glenmark with alcohol 
Olanzapine Glenmarks alkoholom
In a multinational, double-blind, comparative study of schizophrenia, schizoaffective, and related disorders which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant\ improvement (p= 0.001) favouring olanzapine (- 6.0) versus haloperidol (- 3.1). 
U multinacionalnom, dvostruko slijepom, komparativnom ispitivanju shizofrenije, shizoafektivnih i povezanih poremećaja, koje je obuhvaćalo 1481 bolesnika s različitim stupnjevima pridruženih simptoma depresije (srednja početna vrijednost 16,6 po Montgomery-Asberg ljestvici depresije), prospektivna sekundarna analiza vrijednosti promjene raspoloženja od početnog do krajnjeg pokazala je statistički značajno poboljšanje (p=0,001) u korist olanzapina (-6,0) u odnosu na haloperidol (-3,1).
In a study in breast- feeding, healthy women, olanzapine was excreted in breast milk. 
U ispitivanju sa zdravim dojiljama olanzapin se izlučivao u majčino mlijeko.
In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] ≥ 500 milliseconds [msec] at any time post baseline in patients with baseline QTcF < 500 msec) were uncommon (0.1 % to 1 %) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo. 
U kliničkim ispitivanjima klinički značajna produljenja QTc intervala (Fridericia QT korekcija [QTcF] ≥ 500 milisekundi [ms] bilo kada nakon početne vrijednosti u bolesnika s početnom vrijednošću QTcF< 500 ms) bila su manje česta (0,1% do 1%) u bolesnika liječenih olanzapinom, bez značajnih razlika u povezanim srčanim događajima u usporedbi s placebom.
Hyperglycaemia and/or development or exacerbation of diabetes occasionally associated with ketoacidosis or coma has been reported uncommonly, including some fatal cases (see section 4.8). 
Manje su često prijavljivane hiperglikemija i/ili razvoj ili egzacerbacija dijabetesa ponekad povezani s ketoacidozom ili komom, uključujući neke smrtne slučajeve (vidjeti dio 4.8).
Patients treated with any antipsychotic medicines, including olanzapine, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter. 
U bolesnika liječenih bilo kojim antipsihotikom, uključujući lijek Olanzapine Glenmark, potrebno je redovito pratiti razinu lipida prema smjernicama za primjenu antipsihotika, na primjer, na početku liječenja, 12 tjedana nakon početka liječenja olanzapinom te svakih 5 godina nakon toga.
- The other ingredients are mannitol (E 421), microcrystalline cellulose, aspartame (E 951), crospovidone, magnesium stearate 
- Drugi sastojci su: manitol (E421), mikrokristalična celuloza, aspartam (E951), krospovidon,
- Weight gain has been seen in patients taking Olanzapine Glenmark. 
• Zapaženo je povećanje tjelesne težine u bolesnika koji uzimaju lijek Olanzapine Glenmark.
Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (≥ 0.1% and < 1%). 
Vremenska povezanost liječenja olanzapinom i venske tromboembolije (VTE) prijavljivana je manje često (< 0,01% i < 1%).
Olanzapine Glenmark tablet contains aspartame, which is a source of phenylalanine. 
Olanzapin Glenmark tablete sadrže aspartam, koji je izvor fenilalanina.
In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5HT2A than dopamine D2 receptor occupancy. 
U ispitivanju pozitronskom emisijskom tomografijom (PET), jedna peroralna doza (10 mg) olanzapina u zdravih dobrovoljaca dovela je do većeg zauzimanja 5HT2A nego dopaminskih D2 receptora.
What you need to know before you take Olanzapine Glenmark 
Što morate znati prije nego počnete uzimati lijek Olanzapine Glenmark
However, caution should be exercised when olanzapine is prescribed with medicines known to increase QTc interval, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia. 
Međutim, oprez je potreban prilikom propisivanja olanzapina s lijekovima za koje se zna da produljuju QTc-interval, osobito u starijih osoba, u bolesnika s prirođenim sindromom dugog QT-intervala, kongestivnim zatajenjem srca, hipertrofijom srca, hipokalijemijom ili hipomagnezijemijom.
Thromboembolism (including pulmonary embolism and deep vein thrombosis) (see section 4.4) 
tromboembolija (uključujući plućnu emboliju i duboku vensku trombozu) (vidjeti dio 4.4)
Olanzapine Glenmark 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg are available in aluminium foil blisters of 28, 56, 70 and 98tablets 
Olanzapin Glenmark 2,5 mg, 5 mg, 7,5 mg, 10 mg i 15 mg tablete dostupne su u blisterima od aluminijske folije s 28, 56, 70 i 98 tableta.
14 Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high (≥ 1.467 mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to high (≥ 1.467 mmol/l). 
14 Uočeno za normalne početne razine triglicerida natašte (< 1,016 mmol/l) koje su porasle na visoke razine (≥ 1,467 mmol/l) i promjene u vrijednosti triglicerida natašte od početnih graničnih vrijednosti (≥ 1,016 mmol/l-< 1,467 mmol/l) do visokih vrijednosti (≥ 1,467 mmol/l).
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic and risperidone-responsive patients, while being comparable to clozapine-responsive patients. 
Single Photon Emission Computed Tomography) u bolesnika sa shizofrenijom otkrilo je da bolesnici koji reagiraju na olanzapin imaju manju zauzetost strijatalnih D2 receptora od bolesnika koji su reagirali na neke druge antipsihotike i risperidon, dok je zauzetost bila usporediva s onom u bolesnika koji su reagirali na klozapin.
Phenylalanine 
Fenilalanin
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5 HT2A/2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; α1 adrenergic; and histamine H1 receptors. 
U pretkliničkim ispitivanjima olanzapin je pokazao raspon afiniteta za receptore (Ki < 100 nM) serotonina 5HT2A/2C, 5HT3, 5HT6; dopamina D1, D2, D3, D4, D5; kolinergičke muskarinske receptore M1-M5; α1 adrenergičke; i histaminske H1 receptore.
Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and urinary incontinence were observed commonly. 
Često su uočeni upala pluća, povišena tjelesna temperatura, letargija, eritem, vizualne halucinacije i urinarna inkontinencija.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu 
Ova uputa je zadnji puta revidirana u {MM/GGGG} Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu.
7 Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea and vomiting have been reported when olanzapine is stopped abruptly. 
7 Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina i povraćanje prijavljeni su prilikom naglog prekida primjene olanzapina.
In a second 12-month recurrence prevention study in manic episode patients who achieved remission with a combination of olanzapine and lithium and were then randomised to olanzapine or lithium alone, olanzapine was statistically non-inferior to lithium on the primary endpoint of bipolar recurrence (olanzapine 30.0 %, lithium 38.3 %; p = 0.055). 
U drugom 12-mjesečnom ispitivanju prevencije relapsa epizode manije, bolesnici koji su postigli remisiju kombinacijom olanzapina i litija te su potom bili randomizirani u skupinu koja je primala samo olanzapin ili samo litij, olanzapin nije bio statistički inferioran litiju u pogledu primarne mjere ishoda - relapsa bipolarnog poremećaja (olanzapin 30,0%, litij 38,3%; p=0,055).
With long-term exposure (at least 24 weeks), 89.4 % gained ≥ 7 %, 55.3 % gained ≥ 15 % and 29.1 % gained ≥ 25% of their baseline body weight. 
Tijekom dugotrajne izloženosti (najmanje 24 tjedna), u 89,4% bolesnika povećala se tjelesna težina za ≥ 7%, u 55,3% za ≥ 15%, a u 29,1% bolesnika tjelesna težina se povećala za ≥ 25% od njihove tjelesne težine na početku liječenja.
Weight should be monitored regularly e.g. at baseline, 4, 8 and 12 weeks after starting olanzapine treatment and quarterly thereafter. 
Redovito treba pratiti tjelesnu težinu, npr. na početku, 4, 8 i 12 tjedana nakon početka liječenja olanzapinom te svaka 3 mjeseca nakon toga.
Olanzapine Glenmark 20 mg tablets are available in aluminium foil blisters of 28, 35, 56, 70 and 98 tablets 
Olanzapin Glenmark 20 mg tablete dostupne su u blisterima od aluminijske folije s 28, 35, 56, 70 i 98 tableta.
Olanzapine Glenmark belongs to a group of medicines called antipsychotics. 
Olanzapine Glenmark pripada skupini lijekova koji se zovu antipsihotici i koristi se za liječenje sljedećih stanja:
In an 18-month co-therapy study in manic or mixed episode patients stabilised with olanzapine plus a mood stabiliser (lithium or valproate), long-term olanzapine co-therapy with lithium or valproate was not statistically significantly superior to lithium or valproate alone in delaying bipolar recurrence, defined according to syndromic (diagnostic) criteria. 
U 18-mjesečnom ispitivanju istodobne terapije u bolesnika s maničnim ili miješanim epizodama, koji su stabilizirani olanzapinom i stabilizatorom raspoloženja (litij ili valproat) dugotrajna istodobna terapija olanzapinom s litijem ili valproatom nije bila statistički značajno superiorna u odnosu na litij ili valproat primijenjen u monoterapiji za odgađanje relapsa bipolarnog poremećaja definiranog prema (dijagnostičkim) kriterijima sindroma.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 03 December 2009 
Datum prvog odobrenja: 03 Prosinac 2009
Olanzapine demonstrated a greater in vitro affinity for serotonin 5 HT2 than dopamine D2 receptors and greater 5HT2 than D2 activity in vivo, models. 
Olanzapin je in vitro pokazao veći afinitet za serotoninske 5HT2 nego za dopaminske D2 receptore te veće djelovanje na 5HT2 nego D2 u in vivo modelima.
May be harmful for people with phenylketonuria. 
Može naškoditi osobama koje boluju od fenilketonurije.
31, D - 82194 
Industriestr. 31, D-82194,
In healthy elderly (65 and over) versus non-elderly subjects, the mean elimination half-life was prolonged (51.8 versus 33.8 hr) and the clearance was reduced (17.5 versus 18.2 l/hr). 
U zdravih starijih ispitanika (65 godina i starijih) u odnosu na mlađe ispitanike prosječno poluvrijeme eliminacije bilo je produljeno (51,8 naspram 33,8 sati), a klirens smanjen (17,5 naspram 18,2 l/h).
What Olanzapine Glenmark looks like and contents of the pack Olanzapine Glenmark 2.5mg is supplied as: yellow coloured circular flat bevelled edge tablets with ‘A' debossed on one side. 
Kako Olanzapin Glenmark izgleda i sadržaj pakiranja Olanzapin Glenmark 2,5 mg su dostupne kao: žute, okrugle, plosnate tablete kosih rubova, s utisnutom oznakom ‘A' na jednoj strani.
There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3 % versus 0.4 %, respectively). 
U bolesnika liječenih olanzapinom zabilježen je trostruki porast CV štetnih događaja u usporedbi s bolesnicima koji su primali placebo (1,3% naspram 0,4%).
Following short term treatment (median duration 47 days), weight gain ≥ 7 % of baseline body weight was very common (22.2%), ≥ 15% was common (4.2%) and ≥25% was uncommon (0.8%). 
Nakon kratkotrajnog liječenja (medijan trajanja 47 dana) povećanje tjelesne težine ≥ 7% od početne tjelesne težine bilo je vrlo često (22,2%), povećanje ≥ 15% bilo je često (4,2%), a ≥ 25% bilo je manje često (0,8%).
Smoking 
DRESS
In placebo-controlled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5 % vs 1.5 %, respectively). 
U placebom kontroliranim kliničkim ispitivanjima (trajanja od 6 do 12 tjedana) starijih bolesnika (srednja vrijednost dobi 78 godina) s psihozom i/ili poremećajima ponašanja uzrokovanih demencijom zabilježeno je dvostruko povećanje incidencije smrtnosti u bolesnika liječenih olanzapinom u usporedbi s bolesnicima koji su primali placebo (3,5% naspram 1,5%).
Mannitol (E 421) Microcrystalline cellulose Aspartame (E 951) Crospovidone Magnesium stearate 
6.1 Popis pomoćnih tvari manitol (E421) celuloza, mikrokristalična aspartam (E951) krospovidon magnezijev stearat
How to take Olanzapine Glenmark 
Kako uzimati Olanzapin Glenmark
In female versus male subjects the mean elimination half life was somewhat prolonged (36.7 versus 32.3 hrs) and the clearance was reduced (18.9 versus 27.3 l/hr). 
U žena je prosječno poluvrijeme eliminacije nešto duže u odnosu na muškarce (36,7 naspram 32,3 sata), a klirens je smanjen (18,9 naspram 27,3 l/h).
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥ 0.01% and < 0.1%) when olanzapine is stopped abruptly. 
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su prijavljivani (≥ 0,01% i < 0,1%) nakon naglog prekida uzimanja olanzapina.
anticholinergic effects including constipation and dry mouth distension9 
Poremećaji probavnog sustava blagi, prolazni antikolinergički učinci uključujući konstipaciju i suha usta distenzija abdomena9 pankreatitis11
9 Adverse event identified from clinical trials in the Olanzapine Integrated Database. 
Nuspojava je identificirana iz kliničkih ispitivanja u integriranoj bazi podataka za olanzapin.
Seizures have been reported to occur uncommonly in patients when treated with olanzapine. 
Prijavljeno je da se napadaji manje često pojavljuju u bolesnika liječenih olanzapinom.
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 %of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %). 
13 Nakon kratkotrajnog liječenja (medijan trajanja 22 dana), povećanje tjelesne težine ≥ 7% od početne tjelesne težine (kg) bilo je vrlo često (40,6%), porast ≥ 15% od početne tjelesne težine bio je čest (7,1%), a ≥ 25% bio je čest (2,5%).
Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/l - < 2.26 mmol/l) to high (≥ 2.26 mmol/l) were very common. 
Promjene u vrijednosti triglicerida natašte od početnih graničnih vrijednosti (≥ 1,69 -< 2,26 mmol/l) do visokih vrijednosti (≥ 2,26 mmol/l) bile su vrlo česte.
After oral administration, the mean terminal elimination half-life of olanzapine in healthy subjects varied on the basis of age and gender. 
Prosječno poluvrijeme eliminacije olanzapina u zdravih ispitanika nakon peroralne primjene varira ovisno o dobi i spolu.
Dysarthria Stuttering11 
dizartrija mucanje11
6.5 Nature and contents of container Aluminium/aluminium blisters in cartons of 28, 56, 70, 98 tablets per carton. 
6.5 Vrsta i sadržaj spremnika Aluminij/aluminij blisteri u kutijama s 28, 56, 70, 98 tableta.
What Olanzapine Glenmark contains - The active substance is olanzapine - Each Olanzapine Glenmark tablet contains 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg or 20 mg olanzapine 
- Svaka Olanzapin Glenmark tableta sadrži 2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg ili 20 mg olanzapina.
In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1 %; a potential contributing factor could be high plasma valproate levels. 
U jednom kliničkom ispitivanju u bolesnika s bipolarnom manijom, kombinacijska terapija valproatom i olanzapinom uzrokovala je incidenciju neutropenije od 4,1%.
How to store Olanzapine Glenmark 
Kako čuvati Olanzapin Glenmark
Patients gaining ≥7%, ≥15% and ≥25% of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively). 
Tijekom dugotrajne izloženosti lijeku (najmanje 48 tjedana) povećanje tjelesne težine ≥ 7%, ≥ 15% i ≥ 25% od početne bilo je vrlo često (64,4%, 31,7%, odnosno
Neuroleptic malignant syndrome (see section 
sindrom nemirnih nogu neuroleptički maligni sindrom (vidjeti dio 4.4)12
11 Adverse event identified from spontaneous post-marketing reporting with frequency determined utilising the Olanzapine Integrated Database. 
11 Nuspojava je identificirana iz spontanih prijava nakon stavljanja lijeka u promet, a učestalost je određena uz pomoć integrirane baze podataka za olanzapin.
Eosinophilia Leukopenia10 Neutropenia10 
Poremećaji krvi i limfnog sustava eozinofilija leukopenija10 neutropenija10
Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment. 
Često su uočeni prolazni asimptomatski porasti vrijednosti jetrenih aminotransferaza, ALT i AST, osobito u ranoj fazi liječenja.
Olanzapine Glenmark contains the active substance olanzapine. 
Olanzapine Glenmark sadrži djelatnu tvar olanzapin.
- High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking Olanzapine Glenmark. 
• U bolesnika koji uzimaju lijek Olanzapine Glenmark uočena je visoka razina šećera i masnoća u krvi (trigliceridi i kolesterol).
Only take other medicines while you are on Olanzapine Glenmark if your doctor tells you that you can. You might feel drowsy if Olanzapine Glenmark is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers). 
Ako uzimate lijek Olanzapine Glenmark u kombinaciji s antidepresivima, lijekovima za tjeskobu ili lijekovima koji Vam pomažu zaspati (trankvilizeri), možete se osjećati omamljeno.
SmokingIn non-smoking versus smoking subjects (males and females) the mean elimination half-life was prolonged (38.6 versus 30.4 hr) and the clearance was reduced (18.6 versus 27.7 l/hr). 
Prosječno poluvrijeme eliminacije u ispitanika nepušača (muškarci i žene) bilo je duže nego u ispitanika pušača (38,6 naspram 30,4 sata), a klirens je bio manji (18,6 naspram 27,7 l/h).
Changes in total fasting cholesterol levels from borderline at baseline (≥ 5.17- < 6.2 mmol/l) to high (≥ 6.2 mmol/l) were very common. 
Promjene ukupnog kolesterola natašte od početnih graničnih vrijednosti (≥ 5,17-< 6,2 mmol/l) do visokih vrijednosti (≥ 6,2 mmol/l) bile su vrlo česte.
Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking Olanzapine Glenmark and regularly during treatment. 
Prije početka uzimanja lijeka Olanzapine Glenmark te redovito tijekom liječenja, liječnik bi Vam trebao obaviti krvne pretrage kako bi provjerio razinu šećera i određenih masnoća u krvi.
Pancreatitis11 
trombocitopenija11
3 Observed for fasting normal levels at baseline (< 5.17 mmol/l) which increased to high (≥ 6.2 
3 Uočeno za početne normalne razine natašte (< 5,17 mmol/l) koje su porasle na visoke razine
The pharmacokinetics of olanzapine are similar between adolescents and adults. 
Adolescenti (u dobi od 13 do 17 godina): farmakokinetika olanzapina je slična između adolescenata i odraslih.
Olanzapine Glenmark 7.5 mg: yellow coloured circular flat bevelled edge tablets with ‘C' debossed on one side. 
Olanzapin Glenmark 7,5 mg: žute, okrugle, plosnate tablete kosih rubova, s utisnutom oznakom ‘C' na jednoj strani.
5 Observed for fasting normal levels at baseline (< 1.69 mmol/l) which increased to high (≥ 2.26 
Uočeno za početne normalne razine natašte (< 1,69 mmol/l) koje su porasle na visoke razine
Olanzapine Glenmark tablets are for oral use. 
Olanzapine Glenmark obložene tablete uzimaju se kroz usta.
Olanzapine Glenmark 7.5 mg tablets 
Olanzapin Glenmark 7,5 mg tablete
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 7.5 mg olanzapine. 
KVALITATIVNI I KVANTITATIVNI SASTAV Svaka tableta sadrži 7,5 mg olanzapina.
Olanzapine Glenmark contains a source of phenylalanine. 
Olanzapin Glenmark sadrži aspartam Olanzapin Glenmark sadrži izvor fenilalanina.
Olanzapine Glenmark 5 mg: yellow coloured circular flat bevelled edge tablets with ‘B' debossed on one side. 
Olanzapin Glenmark 5 mg: žute, okrugle, plosnate tablete kosih rubova, s utisnutom oznakom ‘B' na jednoj strani.
Olanzapine Glenmark 10 mg tablets 
Olanzapin Glenmark 10 mg tablete
• Weight gain 
• tegobe s prostatom
Tablet Yellow coloured circular flat bevelled edge tablets with ‘C' debossed on one side. 
Tableta Žute, okrugle, plosnate tablete kosih rubova, s utisnutom oznakom ‘C' na jednoj strani.
There is a risk of feeling drowsy when you are given Olanzapine Glenmark. 
Kad uzimate lijek Olanzapine Glenmark postoji rizik da se osjećate omamljeno.
Olanzapine Glenmark 15 mg tablets 
Olanzapin Glenmark 15 mg tablete
Olanzapine Glenmark 20 mg: yellow coloured circular flat bevelled edge tablets with ‘OL' debossed on one side and ‘F' debossed on other side. 
Olanzapin Glenmark 20 mg: žute, okrugle, plosnate tablete kosih rubova, s utisnutom oznakom ‘OL' na jednoj i ‘F' na drugoj strani.
Tablet Yellow coloured circular flat bevelled edge tablets with ‘A' debossed on one side. 
Tableta Žute, okrugle, plosnate tablete kosih rubova, s utisnutom oznakom ‘A' na jednoj strani.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg olanzapine. 
KVALITATIVNI I KVANTITATIVNI SASTAV Svaka tableta sadrži 10 mg olanzapina.
NAME OF THE MARKETING AUTHORISATION HOLDER Glenmark Arzneimittel GmbH 
Nositelj odobrenja za stavljanje lijeka u promet Glenmark Arzneimittel GmbH
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg olanzapine. 
KVALITATIVNI I KVANTITATIVNI SASTAV Svaka tableta sadrži 2,5 mg olanzapina.
Olanzapine Glenmark 2.5 mg tablets 
Olanzapin Glenmark 2,5 mg tablete
NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark 7.5 mg tablets 
NAZIV LIJEKA Olanzapin Glenmark 7,5 mg tablete
Excipient with known effect: Each tablet contains 0.46 mg of aspartame For the full list of excipients, see section 6.1. 
Pomoćna tvar s poznatim učinkom: svaka tableta sadrži 0,46 mg aspartama.
Dystonia (including oculogyration) 11 
distonija (uključujući okulogiraciju)11 tardivna diskinezija11 amnezija9
Olanzapine Glenmark 15 mg: yellow coloured circular flat bevelled edge tablets with ‘OL' debossed on one side and ‘E' debossed on other side. 
Olanzapin Glenmark 15 mg: žute, okrugle, plosnate tablete kosih rubova, s utisnutom oznakom ‘OL' na jednoj i ‘E' na drugoj strani.
Excipient with known effect: Each tablet contains 0.23 mg of aspartame For the full list of excipients, see section 6.1. 
Pomoćna tvar s poznatim učinkom: svaka tableta sadrži 0,23 mg aspartama.
Olanzapine Glenmark 10 mg: yellow coloured circular flat bevelled edge tablets with ‘OL' debossed on one side and ‘D' debossed on other side. 
Olanzapin Glenmark 10 mg: žute, okrugle, plosnate tablete kosih rubova, s utisnutom oznakom ‘OL' na jednoj i ‘D' na drugoj strani.